Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ISA 2020 | Burning questions: ASCT in AL amyloidosis

Vaishali Sanchorawala • 15 Sep 2020

ISA 2020

Amyloidosis Rare Diseases Bortezomib Cyclophosphamide Daratumumab Dexamethasone

ANDROMEDA

Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses the burning questions in the use of autologous stem cell transplant (ASCT) in AL amyloidosis. The successful use of novel agents and data drawn from the ANDROMEDA trial (NCT03201965) is referenced as to why the utility of ASCT in AL amyloidosis may be questioned. However, Dr Sanchorawala does go on to explain how for a small patient population, ASCT is still a very useful tool. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Safety and efficacy of NXC-201, an anti-BCMA CAR-T, in R/R AL amyloidosis

Vaishali Sanchorawala • 11 Dec 2023

Quantifying biomarkers on lambda amyloidogenic light chains to diagnose AL amyloidosis

Vaishali Sanchorawala • 11 Dec 2023

Safety of birtamimab in AL amyloidosis: pooled analysis from multiple studies

Vaishali Sanchorawala • 12 Dec 2023

Key highlights in amyloidosis at ASH 2023: diagnosis & novel immunotherapeutic agents being explored

Ashutosh Wechalekar et al. • 9 Dec 2023

Related Videos

Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH

Carlo Dufour • 15 Apr 2024

Personalized risk assessment for transplantation in primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024

Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024

Hematological manifestations associated with primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024